| 摘要 |
Described is the use of a pharmaceutical composition comprising the aldosterone synthase inhibitor fadrozole or a pharmaceutically acceptable salt thereof alone, for the manufacture of a medicament for the prevention of, delay of progression of, treatment of a disease or condition selected from the group including any one of; (a) congestive heart failure, renal failure, chronic renal failure, restenosis after percutaneous transluminal angioplasty, and restenosis after coronary artery bypass surgery; (b) atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, nephropathy, renal failure, chronic renal failure, hypothyroidism, survival post myocardial infarction (Ml coronary heart diseases, increase of formation of collagen, and remodelling following hypertension; and (c) endothelial dysfunction. The use as described wherein the aldosterone synthase inhibitor is the (+) enantiomer of fadrozole or a pharmaceutically acceptable salt thereof of formula
|
